ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments Post author:admERY Post published:October 23, 2014 Post category:Newsroom ERYTECH announces today the successful completion of a capital increase for a total amount of €30 million. You Might Also Like ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML December 8, 2017 ERYTECH Appoints Stewart Craig as Chief Technical Officer October 26, 2020 ERYTECH Announces Presentation of Additional Data at the American Society of Hematology 57th Annual Meeting December 8, 2015
ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML December 8, 2017
ERYTECH Announces Presentation of Additional Data at the American Society of Hematology 57th Annual Meeting December 8, 2015
